CEO Sean Saint received total reported compensation of $12,191,317 in 2025, driven primarily by a large IPO-related stock option grant valued at approximately $7,955,048 — a single large award tied to the company going public in January 2025 and reported entirely in the first year. For a medical device company with a market cap of approximately $764 million that only became public in January 2025, this level of total compensation — more than 1.6% of the entire company's market value paid to one executive in a single year — appears substantially above what peers at this size and stage typically receive, likely triggering the policy's greater-than-20% above benchmark threshold for the CEO. While the company's stock has significantly outperformed IHI — the iShares US Medical Devices ETF benchmark — over the past year, the absence of disclosed quantitative performance targets for the annual bonus (which paid out at 127.8% of target) makes it difficult to confirm that incentive pay was earned against clear, measurable goals, which the policy treats as a flag equivalent to no meaningful performance conditions.

Ernst & Young LLP has audited Beta Bionics since 2023 — only about three years — well below the 25-year tenure threshold that would raise independence concerns. Non-audit fees (tax services of $71,269) represent roughly 10.5% of audit fees ($677,399), comfortably below the 50% limit. EY is a Big 4 firm appropriate for a company of this size and complexity, and there are no disclosed restatements or other red flags.